Autopsy report · NCT01148901
Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451)
Cause of deathSlow enrollment
“No patient enrolled after 6 months from the start. The decision to withdraw the study was based on a feasibility reevaluation conducted with investigators.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 4
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Conditions
- Ankylosing Spondylitis
- Interventions
- Infliximab
- Participants
- 0
Trials that died the same way
- Mindfulness Training Versus Low (FODMAP) Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols Diet
“The study was withdrawn prior to initiation. No participants were enrolled.” - Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
“Study was withdrawn due to lack of patient enrollment.” - CPAP Population Management
“The study was withdrawn prior to initiation. The protocol was submitted for IRB review but was not approved, and no participants were enrolled.” - Phase 3 Study of ANP Therapy vs. TMZ for Optic Pathway Glioma
“Withdrawn: study halted prematurely, prior to enrollment of first participant” - Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis
“No participants enrolled for more than two years. No plan to continue study.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.